(CercleFinance.com) – Merck announced on Tuesday that a drug it hoped would prevent the transmission of Covid-19 within the same household had not passed the primary endpoint of a phase III study.
Lagevrio, which was tested to prevent transmission between people living in the same home, did not sufficiently contain the virus compared to a placebo, the American laboratory said.
As part of the study, which recruited more than 1,500 participants, the drug only reduced the probability of contracting Covid by 23.6% over two weeks, a level deemed insufficient from a statistical point of view.
The treatment therefore did not meet its primary endpoint in the trial.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
